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Abstract Erythropoietic protoporphyria (EPP) is a hereditary
disorder caused by deficiency of ferrochelatase, the last
enzyme in the heme biosynthetic pathway. The majority of
EPP patients present with a clinical symptom of painful
phototoxicity. Liver damage, the most serious complication of
EPP, occurs in <5% of the patients. This report describes a
case of an EPP patient who complained of worsening
cutaneous symptoms, nervousness, and insomnia. Laboratory
tests showed highly increased protoporphyrin concentration
in erythrocytes and elevated serum transaminases that are
indicative of EPP-related liver damage. The subsequent
finding of decreased serum thyroid-stimulating hormone
(TSH) and increased free triiodothyronine (FT3) and free
thyroxine (FT4) concentrations, as well antibodies against
both thyroid peroxidase (TPO) and TSH receptors, led to the
diagnosis of Graves’ disease. The patient received 500 MBq
of radioiodine (I131). Three months after the radioactive
iodine therapy, the thyroid volume was reduced to 30% of
pretherapeutic volume. Although the patient was slightly
hypothyroidic, his liver enzymes returned to normal, his
erythrocytic protoporphyrin concentration dropped fivefold,
and his skin symptoms improved dramatically. The coexis-
tence of Graves’ disease and EPP is a statistically rare event
as, besides our patient, there was one additional case
reported in the literature. Although the exact mechanism
whereby Graves’ disease interacts with EPP is yet to be
explored, we recommend testing thyroid function in EPP
patients with liver complication to exclude hyperthyroidism
as a potential cause.
Abbreviations
EPP Erythropoietic protoporphyria
XLDPP X-linked dominant protoporphyria
FECH Ferrochelatase
ALAT Alanine aminotransferase
ASAT Aspartate aminotransferase
ULN Upper limit of normal
RDW Red cell distribution width
MCV Mean corpuscular volume
MCH Mean corpuscular hemoglobin
TSH Thyroid stimulating hormone
TPO Thyroperoxidase
FT3 Free triiodthyronine
FT4 Free thyroxine
PAS Periodic acid-Schiff
Introduction
Erythropoietic protoporphyria (EPP) is a rare inherited
disease of heme biosynthesis. The affected enzyme,
ferrochelatase, is the ultimate enzyme of the heme
biosynthetic pathway and catalyses the insertion of iron
into protoporphyrin to form heme (Anderson et al. 2001). A
clinically similar disease, X-linked dominant protoporphyria
(XLDPP), is caused by activating mutations of aminolevulinate
synthase 2, the first enzyme of the pathway (Whatley et al.
2008). In both disorders, accumulation of the substrate of
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ferrochelatase, protoporphyrin IX, leads to dermal phototoxicity,
whichmainly affects the face and back of the hands. Seven years
after the first description of EPP by Magnus et al. in 1961,
Barnes et al. (1968) reported a case of EPP-related terminal
liver failure elicited by hepatic accumulation of protoporphyrin
IX. The life-long risk of terminal liver failure is estimated to be
between 1% and 4% (Holme et al 2006; Doss and Frank
1989). A dramatic increase in the erythrocytic protoporphyrin
concentration, together with a decrease of fecal protoporphyrin
elimination and an increase in the amount of urinary
coproporphyrin I-isomer, is regarded as a sign of impending
EPP liver disease (Gross et al. 1998). Alcohol overconsump-
tion was the first identified risk factor for the development of
EPP-related liver failure (Bonkovsky and Schned 1986). Later,
genetic factors, including null-allele mutations in the ferroche-
latase (FECH) gene, as well as hypermethylation of the
nonmutated FECH allele, were added (Minder et al 2002;
Onaga et al 2004). Limited data available so far indicates that
patients with the variant XLDPP are at a higher risk of
developing liver affection than those with the classic EPP.
We report here that hyperthyroidism, a treatable disease,
caused exacerbation of the cutaneous symptoms, a massive
increase in the level of erythrocytic protoporphyrin
concentration, and signs of liver involvement in a patient
with classic EPP.
Case report
The 40-year-old man complained of worsening skin
phototoxicity during the previous 6 months when he visited
our clinic in early 2006. He presented with the typical EPP
skin lesion on the nose. In addition, he also suffered from
anxiety and insomnia. The patient was severely affected by
phototoxicity during early childhood. As an adult, he had
learned to cope with the disease and was able to carry out
his daily activities without much restraint until late 2005.
The diagnosis of EPP was made 13 years earlier at the
French Center for Porphyrias, Paris, France, on the basis
of reduced ferrochelatase activity in peripheral blood
mononuclear cells. No record was available on the blood
protoporphyrin concentration at the time of diagnosis.
However, his urinary porphyrin concentrations were
reportedly normal. Skin histology at that time showed
abnormalities typical for EPP, including periodic acid-
Schiff (PAS) deposits around the capillaries. The eryth-
rocytic protoporphyrin concentration at his initial visit to
our clinic was increased to a level that we considered as
potentially risky for developing EPP liver affection,
i.e., >40 μmol/L red blood cell (RBC) count. Liver
function was therefore evaluated. As shown in Table 1,
serum alanine aminotransferase (ALAT) was nearly two
times above the upper limit of normal (ULN), and serum
aspartate aminotransferase (ASAT) was slight above the
ULN. The patient reported no excess alcohol consumption.
The patient’s FECH gene was subsequently sequenced,
leading to the identification of a heterozygous mutation, p.
W34X. This is a known mutation of the FECH gene first
described by Gouya et al. (2004). The patient was also
heterozygous for the intronic polymorphism IVS3-48c/t.
This genetic constellation confirmed the diagnosis of
classic EPP. Hematologic values were largely normal,
except for a slight increase in the RBC distribution width
(RDW) and decreases in mean corpuscular volume (MCV)
and mean corpuscular hemoglobin (MCH), a frequent
finding among EPP patients (Holme et al. 2007; Delaby et
al. 2009; Wahlin 2010). At the patient’s second visit to our
clinic 3 months later, both his protoporphyrin concentration
and liver enzyme values remained unchanged. However,
the concentration of urinary porphyrins, in particular
coproporphyrin isomer I, was increased, which was a sign
of cholestasis.
Because of his complains of nervousness and insomnia,
thyroid function tests were performed. The results showed a
decrease in serum TSH and a concomitant increase of both
FT3 and FT4 (Table 1). In addition, antibodies against both
thyroperoxidase (TPO) and TSH receptor (TRAb) were
detected. Radioiodine uptake was increased, and the uptake
was diffusely distributed over the entire gland, as demon-
strated by scintigraphy. (Table 1). A diagnosis of Graves’
disease was therefore made. Radioactive iodine therapy was
chosen over thyrostatic drugs taking into consideration that
these drugs, as an adverse effect, may cause further damage
to the patient’s liver. He received 500 MBq of I131,
corresponding to an ablative thyroid dose of 200 Gy. Six
weeks later, mild hypothyroidism developed. He was
substituted with thyroxine. Three months after the
radioactive iodine therapy, the patient remained slightly
hypothyroidic, and the dosage of thyroxine was therefore
increased. Also, his thyroid volume, as determined by
sonography, was decreased to 30% of the pretherapeutic
volume (8 vs. 27 ml; Table 1). At the same time, a fivefold
drop in the concentration of erythrocytic protoporphyrin was
measured. Concomitantly, urinary porphyrin concentration
and liver enzymes all returned to normal. Meanwhile, the
patient noticed a dramatic improvement in his skin condi-
tion, i.e., the cutaneous phototoxicity was reduced to the
degree he was accustomed to.
Discussion
Graves’ disease is a relatively common disorder that occurs
at any age but is especially common in the third and fourth
decades of life. It can be found in approximately 1% of the
population, or 1:89 individuals (Hollowell et al. 2002).
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However, the chance for coexistence of Graves’ disease and
EPP is very low, i.e., 1:13 million individuals, since EPP is
a relatively rare inborn disorder with an estimated preva-
lence of about 1:150,000 individuals (Schneider-Yin et al.
2009). The scarcity is evidenced by the fact that so far, only
one additional case of EPP combined with Graves’ disease
has been reported in the literature, which was in 1969
(Yamada et al. 1971). In that report, the 16-year-old
Japanese patient presented with a clinical course very
similar to that of our patient, i.e., aggravation of EPP
symptoms and signs of protoporphyrin-induced liver
disease at the time when Graves’ disease was diagnosed.
The symptoms included dark skin rashes, signs of hyper-
thyroidism, jaundice, abnormal liver function, and a
massive increase in erythrocytic protoporphyrin concentra-
tion (Table 1). As in our patient, the conditions in the
Japanese patient improved dramatically after successful
treatment of hyperthyroidism, i.e., normal liver function
was restored and erythrocytic protoporphyrin concentration
diminished (Yamada et al. 1971). The occurrence of
Graves’ disease in EPP, although very rare, caused an
exacerbation of skin symptoms and more importantly,
deterioration in liver function, in both patients, so that they
were at risk of developing liver disease, the most serious
and potentially life-threatening complication of EPP.
Interaction between hyperthyroidism and EPP is theo-
retically possible, as both diseases affect the liver and bone
marrow. In EPP, bone marrow is the main source of
protoporphyrin overproduction during erythropoiesis,
whereas the liver/biliary tract is the only excretory route
for excess protoporphyrin due to its hydrophobic nature.
EPP patients present frequently with normo- to microcytic
anemia due to disturbance in iron metabolism or iron
distribution in the body (Lyoumi et al 2007; Holme et al
2007) or to a decreased rate of heme synthesis as the result
of deficient ferrochelatase activity.
Mild liver dysfunction featured by elevated liver
enzymes occurs frequently in hyperthyroid patients,
whereas icterus can be observed in severe thyrotoxicosis
(Gurlek et al. 1997; Beaver and Pemberton 1933).
Erythropoiesis on the other hand, is increased in hyper-
thyroidism in order to meet the demand of an increase in
oxygen delivery to the peripheral tissues. The enhanced
erythropoiesis is reflected by a hypercellular bone marrow,
in particular, an increased number of erythrocyte precur-
sors. In general, hyperthyroid patients show increases in
both the total RBC mass and total blood volume. As a
result, their hemoglobin concentration could remain
normal. Additional signs of enhanced erythropoiesis,
including increased hemoglobin synthesis, shortened
plasma iron clearance time, and increased iron turnover
and RBC radioiron incorporation, can be observed in
some hyperthyroid patients (18). In other patients, how-
ever, there is evidence of ineffective erythropoiesis, as
seen by reduced MCVand erythrocyte survival time (Ford and
Carter 1988). Iron deficiency, which negatively affects
erythropoiesis, is also frequently observed in hyperthyroidism.
Experimental evidence, which indicate a possible link
between thyroid hormone and the heme biosynthesis, came
from a study of Bauer et al. (1998). In that study, the
thyroid hormone receptor α (c-ErbA/TRα) was shown to
be involved in the terminal differentiation of erythroid
progenitors, i.e., upon binding to its ligand T3, c-ErbA/
TRα induced a switching from proliferation to differenti-
ation in gc-ErbA erythroblasts. Among the enzymes
involved in erythroid differentiation, aminolevulinic acid
synthase (ALAS) is the initial and rate-limiting enzyme of
heme biosynthesis. In a study by Zenke et al. (1990), the
amount of ALAS transcript in v2-ErbA-expressing eryth-
roblasts was markedly increased in response to T3.
In both protoporphyrias—EPP and XLDPP—protopor-
phyrin IX accumulates in erythroblasts during the heme
biosynthesis as the result of either a deficient ferrochelatase
or an overactivity of ALAS-2 (the erythroid-specific
ALAS). Based on the available information, it remains
unclear whether hyperthyroidism causes exacerbation of
EPP by increasing the rate of heme synthesis, by impairing
liver excretory function for protoporphyrin, or by other
unknown mechanisms. Therefore, we recommend testing
thyroid function in protoporphyria patients with an accom-
panying liver malfunction in order to exclude hyperthy-
roidism as a potential cause.
References
Anderson K, Sassa S, Bishop D, Desnick R (2001) The porphyrias. In:
Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Childs B,
Kinzler KW, Vogelstein B, assoc. eds. The metabolic and
molecular basis of inherited disease, 8th edn. New York:
McGraw-Hill, 2991-3062
Barnes HD, Hurworth E, Millar JH (1968) Erythropoietic porphyrin
hepatitis. J Clin Pathol 21:157–159
Bauer A, Mikulits W, Lagger G, Stengl G, Brosch G, Beug H (1998)
The thyroid hormone receptor functions as a ligand-operated
developmental switch between proliferation and differentiation of
erythroid progenitors. EMBO J 17:4291–4303
Beaver DC, Pemberton JD (1933) The pathologic anatomy of the liver
in exophthalmic goiter. Ann Intern Med 7:687–708
Bonkovsky HL, Schned AR (1986) Fatal liver failure in protopor-
phyria. Synergism between ethanol excess and the genetic defect.
Gastroenterology 90:191–201
Delaby C, Lyoumi S, Ducamp S, Martin-Schmitt C, Gouya L,
Deybach JC, Beaumont C, Puy H (2009) Excessive erythrocyte
PPIX influences the hematologic status and iron metabolism in
patients with dominant erythropoietic protoporphyria. Cell Mol
Biol (Noisy-le-grand) 55:45–52
Doss MO, Frank M (1989) Hepatobiliary implications and complica-
tions in protoporphyria, a 20-year study. Clin Biochem 22:223–
229
J Inherit Metab Dis (201 ) 3 (Suppl 3):S465–S4690 3    S468
Ford HC, Carter JM (1988) The haematology of hyperthyroidism:
abnormalities of erythrocytes, leucocytes, thrombocytes and
haemostasis. Postgrad Med J 64:735–742
Gouya L, Puy H, Robreau AM et al (2004) Modulation of penetrance
by the wild-type allele in dominantly inherited erythropoietic
protoporphyria and acute hepatic porphyrias. Hum Genet
114:256–262
Gross U, Frank M, Doss MO (1998) Hepatic complications of
erythropoietic protoporphyria. Photodermatol Photoimmunol
Photomed 14:52–57
Gurlek A, Cobankara V, Bayraktar M (1997) Liver tests in
hyperthyroidism: effect of antithyroid therapy. J Clin Gastro-
enterol 24:180–183
Hollowell JG, Staehling NW, Flanders WD et al (2002) Serum TSH, T
(4), and thyroid antibodies in the United States population (1988
to 1994): National Health and Nutrition Examination Survey
(NHANES III). J Clin Endocrinol Metab 87:489–99
Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN (2006)
Erythropoietic protoporphyria in the U.K.: clinical features and
effect on quality of life. Br J Dermatol 155:574–581
Holme SA, Worwood M, Anstey AV, Elder GH, Badminton MN
(2007) Erythropoiesis and iron metabolism in dominant erythro-
poietic protoporphyria. Blood 110:4108–4110
Lyoumi S, Abitbol M, Andrieu V et al (2007) Increased plasma
transferrin, altered body iron distribution, and microcytic
hypochromic anemia in ferrochelatase-deficient mice. Blood
109:811–818
Magnus IA, Jarrett A, Prankerd TA, Rimington C (1961) Erythropoi-
etic protoporphyria. A new porphyria syndrome with solar
urticaria due to protoporphyrinaemia. Lancet 2:448–451
Minder EI, Gouya L, Schneider-Yin X, Deybach JC (2002) A
genotype-phenotype correlation between null-allele mutations in
the ferrochelatase gene and liver complication in patients with
erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand)
48:91–96
Onaga Y, Ido A, Uto H et al (2004) Hypermethylation of the wild-type
ferrochelatase allele is closely associated with severe liver
complication in a family with erythropoietic protoporphyria.
Biochem Biophys Res Commun 321:851–858
Schneider-Yin X, Harms J, Minder EI (2009) Porphyria in Switzerland,
15 years experience. Swiss Med Wkly 139:198–206
Wahlin S (2010) Erythropoietic protoporphyria, clinical and epidemiolog-
ical aspects. Thesis, Karolinska Institutet (http://diss.kib.ki.se/2010/
978-91-7409-817-4/thesis.pdf, accessed 20. September 2010).
Whatley SD, Ducamp S, Gouya L et al (2008) C-terminal deletions in
the ALAS2 gene lead to gain of function and cause X-linked
dominant protoporphyria without anemia or iron overload. Am J
Hum Genet 83:408–414
Yamada K, Nakamura Y, Sekiguchi T, Fueki R, Kobayashi S (1971)
Erythropoietic protoporphyria associated with hyperthyroidism
and jaundice. Naika 28:1171–1174
Zenke M, Muñoz A, Sap J, Vennström B, Beug H (1990) v-erbA
oncogene activation entails the loss of hormone-dependent
regulator activity of c-erbA. Cell 61:1035–1049
J Inherit Metab Dis (201 ) 3 (Suppl 3):S465–S4690 3    S469
